Scope and claims of U.S. Patent 12,440,441 (amlodipine besylate oral liquid, ≤5% water; glycerin-rich vehicle) and US patent landscape
U.S. Patent 12,440,441 is directed to an oral liquid formulation of amlodipine (as amlodipine besylate) at about 1 mg/mL in a liquid vehicle with ≤5% w/w water, with a vehicle dominated by glycerin (multiple dependent claim windows), plus optional excipient selections (sweetener, antioxidant, and co-solvent) with defined quantitative ranges. The asserted monopoly is broad at the “formulation” level (composition and excipient types) and then narrows to specific glycerin and excipient concentration bands. The patent also includes method-of-use claims covering hypertension and several angina/coronary artery disease indications for adult and pediatric patients.
What is U.S. Patent 12,440,441 claim scope for an amlodipine oral liquid with ≤5% water?
Core independent claim (Claim 1) defines a composition “box”
Claim 1 protects:
- Dosage strength: about 1 mg/mL amlodipine, as amlodipine besylate
- Oral liquid pharmaceutical formulation (not a solid, not a spray-dried solid, not a suspension outside a “liquid formulation” framing)
- Water content: ≤ about 5% w/w
- Liquid vehicle plus at least one pharmaceutically acceptable excipient
What is broad vs. narrow in Claim 1?
-
Broad elements:
- “Oral liquid pharmaceutical formulation” is not limited to a particular container, dosing regimen, flavor format, or taste-masking mechanism.
- “At least one excipient” is open-ended as to identity, except for dependent claims that narrow excipient types and amounts.
- “Liquid vehicle” is broadly defined in Claim 1, but the functional narrowing appears through dependent claims.
-
Hard boundary elements:
- Strength around 1 mg/mL
- Water content ≤5% w/w (this is the principal formulation-exclusivity lever for non-gel/syrup/diluent approaches)
- Amlodipine besylate salt form is explicitly required.
Dependent claims convert the composition “box” into multiple enforceable sub-boxes
Dependent claims add specific quantitative constraints that can be enforced as narrower fallbacks if the broader Claim 1 is challenged.
Key dependent limitations include:
- Exact strength: Claim 2 requires 1 mg/mL (not just “about”)
- Vehicle co-solvent set: Claim 3 permits vehicles comprising ethanol, glycerin, propylene glycol, ethylene glycol, polyethylene glycol, or combinations
- Glycerin-heavy bands: Claims 4–8 define glycerin concentration windows from ~78% to ~98% w/w and narrower sub-ranges
- Sweetener type and amount bands: Claims 9–15 define sweetener amount from 0.1% to 11% w/w, with multiple tighter bands
- Antioxidant type and amount bands: Claims 16–18 define antioxidant amount 0.01% to 0.09% w/w, with tighter windows
- Co-solvent presence and amount bands: Claims 19–23 define co-solvent amount 1% to 15% w/w, with narrower windows
- Even tighter water limits: Claims 24–25 specify ≤4% and ≤3% w/w
Enforcement implication: An accused product need not match every dependent feature if Claim 1 is found infringed; but if novelty/nonobviousness attacks weaken Claim 1, enforcement may still survive through narrower dependent claim bands if the accused composition lands in those numeric windows.
How do Claims 4–8 (glycerin % w/w) define the practical infringement surface?
Glycerin concentration windows are the dominant “composition fingerprint”
Claims 4–8 are cumulative narrowing options that can map to actual commercial formulations:
| Claim |
Glycerin in liquid vehicle (w/w) |
Range width |
| 4 |
~78% to ~98% |
broad high-glycerin |
| 5 |
~80% to ~98% |
narrower |
| 6 |
~82% to ~94% |
narrower |
| 7 |
~84% to ~92% |
tighter |
| 8 |
~84% to ~90% |
tightest band |
Key takeaways for freedom-to-operate analysis
- The patent landscape for amlodipine oral liquids is likely crowded at the “taste and stability” level, but glycerin-dominant, ultra-low-water vehicles are a more defensible formulation niche.
- A generic or follow-on product using water-containing syrups (typical aqueous suspensions/solutions) risks instant exclusion from the ≤5% w/w water limitation.
- A product using a different polyol blend (e.g., PEG-propylene glycol rich) still may infringe if glycerin is present within the claimed w/w bands, and water remains ≤5% w/w.
What excipients and concentration ranges are protected in U.S. 12,440,441?
Sweeteners (Claims 9–15)
- Sweetener agent is part of Claim 1 excipient concept via dependency.
- Sweetener amount ranges:
- Claim 10: 0.1% to 11% w/w
- Claim 11: 4% to 11% w/w
- Claim 12: 8% to 11% w/w
- Claim 13: 5.5% to 7.0% w/w
- Claim 14: 5.6% to 6.6% w/w
- Claim 15: 5.6% to 6.0% w/w
Practical scope: If a competitor uses a different sweetener class but still uses “a sweetener agent” within these ranges, infringement depends on whether the formulation is captured by Claim 1 (any pharmaceutically acceptable excipient) or only by dependent claims (sweetener within quantitative bands). If the competitor uses no sweetener, dependent claims 10–15 are irrelevant, but Claim 1 may still be asserted.
Antioxidants (Claims 16–18)
- Antioxidant amount:
- Claim 16: 0.01% to 0.09% w/w
- Claim 17: 0.01% to 0.07% w/w
- Claim 18: 0.01% to 0.05% w/w
Practical scope: Low-dose antioxidant inclusion is common in liquid formulations. The numeric windows create a direct mapping test: if the antioxidant is present within these bands, dependent claims may apply.
Co-solvents (Claims 19–23)
- Co-solvent amount:
- Claim 20: 1% to 15% w/w
- Claim 21: 1% to 10% w/w
- Claim 22: 1% to 8% w/w
- Claim 23: 1% to 5% w/w
Practical scope: This is a formulation flexibility lever for a competitor. If the competitor uses a co-solvent outside these windows or omits co-solvent, infringement may narrow to Claim 1 depending on how “liquid vehicle” is structured.
What method-of-use claims does U.S. 12,440,441 cover for amlodipine?
Claims 26–30 protect administration of the formulation of Claim 1 for adult and pediatric patients across:
- Hypertension (Claims 26–27)
- Symptomatic treatment of chronic stable angina (Claim 28)
- Vasospastic angina (Claim 29)
- Coronary artery disease (Claim 30)
Claim drafting notes that matter for litigation
- These are classic use claims: “administering to a patient… a therapeutically effective amount of the formulation of claim 1.”
- The indication set is standard across amlodipine labeling concepts; what is novel is tying those indications to this specific ultra-low-water oral liquid formulation.
- Adult and pediatric coverage increases litigation exposure because pediatric-specific liquid forms are frequently sought for dosing precision and adherence.
How could competitors design around U.S. 12,440,441?
Design-around analysis is constrained to claim text you provided.
Primary technical carve-outs
-
Water content >5% w/w
- Claim 1 and dependent Claims 24–25 anchor exclusivity to ≤5%, ≤4%, and ≤3% water. Exceeding that threshold is the clearest avoidance mechanism.
-
Amlodipine form and concentration mismatch
- Claim 1 requires about 1 mg/mL amlodipine besylate. A different salt (not “amlodipine besylate”) or materially different strength (not “about 1 mg/mL”) reduces capture.
-
Glycerin outside the claimed bands (Claims 4–8)
- If the vehicle is polyol-rich but keeps glycerin below ~78% w/w (or eliminates glycerin entirely), dependent claims 4–8 are avoided. Claim 1 still remains a risk unless Claim 1 is interpreted as requiring the dependent glycerin-heavy vehicle (the claim text you provided does not require glycerin in Claim 1).
-
Omit the specific excipient classes and/or keep outside their numeric bands (Claims 10–23)
- Removing sweetener/antioxidant/co-solvent may avoid dependent claim coverage while leaving Claim 1 as the residual risk.
Litigation posture implication
- If an accused product is clearly outside the ≤5% water limitation, it likely avoids both Claim 1 and its dependent water limitations.
- If it stays within ≤5% water but changes vehicle composition, the dispute becomes construction-heavy: whether Claim 1’s “liquid vehicle” and “excipient” scope permits the new vehicle composition without requiring glycerin dominance.
What adjacent patent families likely interact with U.S. 12,440,441 for amlodipine oral liquids?
Amlodipine oral liquids sit at the intersection of:
- formulation patents (palatability, stability, vehicle selection, low-water or non-aqueous approaches),
- pediatric dosing enablement,
- generic salt and strength approaches,
- and use patents tied to standard indications.
Within that ecosystem, the strongest competitive risk typically comes from:
- other glycerin-rich polyol vehicle patents at low water contents,
- oral liquid/pediatric dosing enablement patents that claim similar concentration ranges,
- and salts/formulation variants that still land on “amlodipine besylate oral liquid” with similar vehicles.
However: without the patent’s bibliographic metadata, priority dates, assignees, and the prosecution history (and without additional patent numbers), a complete US “patent landscape” map (other US publications, related families, expiration dates, and litigation status) cannot be produced accurately from the claim text alone.
Patent estate strength for US exclusivity: what does this claim set imply?
Likely strong points
- Tight formulation constraints on:
- ultra-low water
- high glycerin vehicle
- defined concentration of amlodipine (about 1 mg/mL / 1 mg/mL)
- Numeric dependent claim bands increase the chance that at least one claim lands on an accused formulation even when a competitor tweaks excipients.
Likely litigation issues to expect (construction-heavy)
- Scope of “liquid vehicle” in Claim 1 relative to dependent glycerin requirements.
- Whether “water content” is interpreted as total water or residual moisture in the vehicle, and how it is measured.
- Whether “about 1 mg/mL” is infringed by typical manufacturing tolerances.
How many separate claim “themes” are protected in U.S. 12,440,441?
Based on the provided claims, the patent protects at least five distinct formulation themes:
- Amlodipine besylate oral liquid at ~1 mg/mL
- Ultra-low water (≤5% w/w)
- Glycerin-rich vehicle (78–98% and narrower bands 80–98, 82–94, 84–92, 84–90)
- Excipient engineering
- sweetener (0.1–11% and tighter bands)
- antioxidant (0.01–0.09% and tighter bands)
- co-solvent (1–15% and tighter bands)
- Therapeutic use for hypertension and angina/CAD in adults and pediatrics
Each theme can support claim-by-claim infringement arguments and can influence claim construction outcomes.
Orange Book status, Paragraph IV risk, and FDA exclusivity: what can be concluded from claim text?
None can be concluded from the claim text alone. Orange Book listings depend on the specific NDA/ANDA/BLA product, active ingredient and dosage form registration, and the patent’s listed claims (and expiration/exclusivity dates). Paragraph IV and litigation posture depend on the specific ANDA(s) filed against the reference product. Those facts are not contained in the claim text provided.
Key Takeaways
- U.S. 12,440,441 is a formulation patent for amlodipine besylate oral liquid at ~1 mg/mL, anchored to ≤5% w/w water.
- The strongest, most “fingerprint-like” dependent limitations are glycerin-rich vehicles (Claims 4–8) and tight water ceilings (Claims 24–25).
- Excipient concentration bands create additional infringement vectors: sweetener (Claims 10–15), antioxidant (Claims 16–18), and co-solvent (Claims 20–23).
- Method-of-use claims (Claims 26–30) cover standard amlodipine indications (hypertension, chronic stable angina, vasospastic angina, coronary artery disease) for adult and pediatric patients, but all depend on use of the Claim 1 formulation.
- The most direct design-around is to move the product outside ≤5% w/w water and/or avoid glycerin concentration bands while also managing strength and salt form.
FAQs
1) Does U.S. 12,440,441 require glycerin for infringement?
Claim 1 requires a “liquid vehicle” and an excipient system, while glycerin is explicitly defined in dependent claims (Claims 3–8). Independent coverage depends on how “liquid vehicle” is construed relative to dependent limitations.
2) If a competitor uses ≤5% water but amlodipine concentration is 0.5 mg/mL, is it avoided?
Claim 1 requires about 1 mg/mL amlodipine besylate; a materially different strength may avoid Claim 1, but factual tolerance/“about” construction drives the outcome.
3) What is the highest-risk parameter for a generic liquid attempting design-around?
The water content cap (≤5% w/w) is the clearest numerical boundary in Claim 1 and the dependent claims.
4) Can a competitor avoid dependent claims by using different excipients?
Dependent claims 10–23 require specific excipient types and concentration ranges. A formulation outside those bands can avoid those dependent claims while potentially still risking Claim 1.
5) Do the method-of-use claims create risk even if the formulation is non-infringing?
Use claims require administration of the formulation of Claim 1. If Claim 1 is not infringed, the method claims are not met as written.
References
No sources were cited because the only input provided was the claim text.
